NCT05670821View on ClinicalTrials.gov

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

October 6, 2025

Study Completion Date

October 6, 2025

Conditions
Generalized Pustular Psoriasis
Interventions
DRUG

Spesolimab

Spesolimab

Trial Locations (1)

1416017

Nippon Boehringer Ingelheim Co., Ltd., Tokyo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05670821 - PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms | Biotech Hunter | Biotech Hunter